<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014089</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1325-P101</org_study_id>
    <secondary_id>HHSO100201600029C</secondary_id>
    <nct_id>NCT03014089</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1/2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moderna Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Moderna Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in
      healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI) and adverse events considered related to study drug</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of seroconversion to ZIKV measured by neutralization assay in comparison with baseline sample</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Zika Virus</condition>
  <arm_group>
    <arm_group_label>mRNA-1325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1325</intervention_name>
    <description>Escalating dose levels</description>
    <arm_group_label>mRNA-1325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  18 to 49 years of age

          -  Body mass index between 18 and 35 kg/m2

          -  In good health as determined by medical history

          -  Female subjects must be non pregnant and non lactating and meet one of the following
             criteria: a) post menopausal b) surgically sterile

          -  Women of childbearing potential must agree to be heterosexually inactive or agree to
             consistently use any of the following methods of contraception from at least 21 days
             prior to enrollment and through 3 months after the final vaccination

          -  Male subjects must use an acceptable method of birth control throughout the entire
             study and agree to refrain from donation of sperm from the time of first vaccination
             until 3 months following the last vaccination

          -  Agrees to comply with the study procedures and provides written informed consent

          -  Has access to a consistent and reliable means of telephone contact and agrees to stay
             in contact with the study site for the duration of the study, to provide updated
             contact information as necessary, and has no current plans to move from the study area
             for the duration of the study

        Exclusion

          -  Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care

          -  A history of active cancer (malignancy) in the last 10 years

          -  Female of childbearing potential and has a positive pregnancy test at screening or on
             the day of vaccination

          -  Administration of an investigational product within 60 days, or 5 half-lives,
             whichever is longer

          -  Administration of any live attenuated vaccines within 4 weeks before enrollment or
             inactive vaccines within 2 weeks before enrollment, or plans to receive any vaccine
             during the active vaccination period

          -  Prior administration of a vaccine for Zika or dengue vaccine, a history of confirmed
             Zika or dengue infection, or has lived in or visited any Zika-endemic area greater
             than 4 weeks in duration

          -  Prior administration of investigational agent using formulations similar to mRNA-1325

          -  A history of hypersensitivity or serious reactions to previous vaccinations

          -  Any known or suspected autoimmune disease or immunosuppressive condition, acquired or
             congenital, as determined by medical history and/or physical examination

          -  A history of inflammatory arthritis

          -  Any neurologic disorder

          -  A history of febrile disease with arthritis or arthralgia within 2 weeks of dose
             administration.

          -  Prior administration of immunoglobulins and/or any blood products within the 3 months
             preceding the administration of the study drug or plans to receive such products at
             any time during the study

          -  Any chronic administration of an immunosuppressant or other immune modifying drug

          -  Any acute illness at the time of enrollment

          -  Any significant disorder of coagulation requiring ongoing or intermittent treatment

          -  A history of idiopathic urticaria

          -  A history of alcohol abuse or drug addiction

          -  A positive test result for drugs of abuse

          -  The subject has any abnormality or permanent body art (eg, tattoo) that, in the
             opinion of the investigator, would obstruct the ability to observe local reactions at
             the injection site

          -  Any condition that, in the opinion of the investigator, would pose a health risk to
             the subject if enrolled or could interfere with evaluation of the study drug or
             interpretation of study results

          -  A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or
             human immunodeficiency virus types 1 or 2 antibodies

          -  Donation of blood or blood products &gt; 450 mL within 30 days of dosing.

          -  Abnormal vital signs or screening safety laboratory test results including liver
             enzyme tests

          -  Is an employee or first degree relative of the Sponsor, CRO, or study site personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-1325</keyword>
  <keyword>Zika vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

